Cydan,
LLC , an orphan drug accelerator that identifies and de-risks
programs with therapeutic and commercial potential, today announced its
launch with $16 million in financing led by New Enterprise Associates
(NEA) and Pfizer Venture Investments, with participation from Alexandria
Real Estate Equities, Inc. The accelerator will focus on identifying
promising assets with well-understood biology and proof-of-concept data
in in vivo models from academia, industry and other sources.
Sign-up for Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities investment picks